Late Surgical-Site Infection in Immediate Implant-Based Breast Reconstruction
Overview
Authors
Affiliations
Background: Surgical-site infection causes devastating reconstructive failure in implant-based breast reconstructions. Large national database studies offer insights into complication rates, but only capture outcomes within 30 days postoperatively. This study evaluates both early and late surgical-site infection in immediate implant-based reconstruction and identifies predictors.
Methods: As part of the Mastectomy Reconstruction Outcomes Consortium Study, 1662 implant-based breast reconstructions in 1024 patients were evaluated for early versus late surgical-site infection. Early surgical-site infection was defined as infection occurring within 30 days postoperatively; late surgical-site infection was defined as infection occurring 31 days to 1 year postoperatively. Minor infection required oral antibiotics only, and major infection required hospitalization and/or surgical treatment. Direct-to-implant patients had 1-year follow-up, and tissue expander patients had 1-year post-exchange follow-up.
Results: Among 1491 tissue expander and 171 direct-to-implant reconstructions, overall surgical-site infection rate for tissue expander was 5.7 percent (85 of 1491) after first-stage, 2.5 percent (31 of 1266) after second-stage, and 9.9 percent (17 of 171) for direct-to-implant reconstruction. Over 47 to 71 percent of surgical-site infection complications were late surgical-site infection. Multivariate analysis identified radiotherapy and increasing body mass index as significant predictors of late surgical-site infection. No significant difference between the direct-to-implant and tissue expander groups in the occurrence of early, late, or overall surgical-site infection was found.
Conclusions: The majority of surgical-site infection complications in immediate implant-based breast reconstructions occur more than 30 days after both first-stage and second-stage procedures. Radiotherapy and obesity are significantly associated with late-onset surgical-site infection. Current studies limited to early complications do not present a complete assessment of infection associated with implant-based breast reconstructions or their long-term clinical outcomes.
Clinical Question/level Of Evidence: Risk, II.
Conversion from Alloplastic to Autologous Breast Reconstruction: What Are the Inciting Factors?.
Bitoiu B, Schlagintweit S, Zhang Z, Bovill E, Isaac K, Macadam S Plast Surg (Oakv). 2024; 32(2):213-219.
PMID: 38681249 PMC: 11046274. DOI: 10.1177/22925503221107214.
Comorbid Conditions and Complications in Body Contouring Surgery: A Retrospective Review.
Garoosi K, Mundra L, Jabbari K, Winocour J, Iorio M, Mathes D Aesthet Surg J Open Forum. 2023; 5:ojad080.
PMID: 37711766 PMC: 10499002. DOI: 10.1093/asjof/ojad080.
Medical Imaging of Inflammations and Infections of Breast Implants.
Giovannini E, Travascio L, Follacchio G, Bauckneht M, Criscuoli B, De Cataldo C Diagnostics (Basel). 2023; 13(10).
PMID: 37238291 PMC: 10217528. DOI: 10.3390/diagnostics13101807.
Johnstone T, Lipman K, Makarewicz N, Shah J, Turner E, Posternak V Plast Reconstr Surg Glob Open. 2023; 11(1):e4764.
PMID: 36776590 PMC: 9911200. DOI: 10.1097/GOX.0000000000004764.
Is Iatrogenic Implant Contamination Preventable Using a 16-Step No-Touch Protocol?.
Singh D, Zhang R, Hori K, Parsa F Eplasty. 2022; 22:e38.
PMID: 36160667 PMC: 9490878.